Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241943 | 0.90 | TSHR (0.64) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL5929495 | 0.89 | TSHR (0.67) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL13475545 | 0.88 | TSHR (0.62) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL5266458 | 0.87 | TSHR (0.70) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL6738557 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL13475550 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL822786 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL2712500 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL4102060 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR | |
| SCHEMBL13475548 | 0.86 | TSHR (0.60) | TSHRTDP1CYP2C9SMN1; SMN2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032033-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2021-02-25 | — | — | WO | disclosed |
| CN-109071772-A | Resin combination, prepreg, clad with metal foil plywood, resin sheet and printed circuit board | 三菱瓦斯化学株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3173416-A1 | BORONDIFLUORIDE COMPLEXES OF CURCUMINOID COMPOUNDS, METHOD OF PREPARATION AND USES THEREOF | Université d'Aix Marseille (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2015025962-A1 | AMIDINE COMPOUND OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2015-02-26 | — | — | WO | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130172342-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010123139-A1 | ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP | 持田製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| US-20100033086-A1 | POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100033086-A1 | POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2123691-A1 | POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-0342943-A1 | Thermosetting resin composition | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172342-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, SCN2B, SCN1A | TSHR 1237/4885TDP1 4602/4885CYP2C9 1173/4885 |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | TSHR 3272/4885TDP1 1800/4885CYP2C9 2720/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885TDP1 4837/4885CYP2C9 3111/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885TDP1 4837/4885CYP2C9 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.